Cargando…
A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas
The nonfunctioning pituitary adenoma (NFPA) recurrence rate is relatively high after surgical resection. Here, we constructed effective long noncoding RNA (lncRNA) signatures to predict NFPA prognosis. LncRNAs expression microarray sequencing profiles were obtained from 66 NFPAs. Sixty-six patients...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564111/ https://www.ncbi.nlm.nih.gov/pubmed/34745223 http://dx.doi.org/10.3389/fgene.2021.754503 |
_version_ | 1784593546157752320 |
---|---|
author | Cheng, Sen Guo, Jing Wang, Dawei Fang, Qiuyue Liu, Yulou Xie, Weiyan Zhang, Yazhuo Li, Chuzhong |
author_facet | Cheng, Sen Guo, Jing Wang, Dawei Fang, Qiuyue Liu, Yulou Xie, Weiyan Zhang, Yazhuo Li, Chuzhong |
author_sort | Cheng, Sen |
collection | PubMed |
description | The nonfunctioning pituitary adenoma (NFPA) recurrence rate is relatively high after surgical resection. Here, we constructed effective long noncoding RNA (lncRNA) signatures to predict NFPA prognosis. LncRNAs expression microarray sequencing profiles were obtained from 66 NFPAs. Sixty-six patients were randomly separated into a training (n = 33) and test group (n = 33). Univariable Cox regression and a machine learning algorithm was used to filter lncRNAs. Time-dependent receiver operating characteristic (ROC) analysis was performed to improve the prediction signature. Three lncRNAs (LOC101927765, RP11-23N2.4 and RP4-533D7.4) were included in a prognostic signature with high prediction accuracy for tumor recurrence, which had the largest area under ROC curve (AUC) value in the training/test group (AUC = 0.87/0.73). The predictive ability of the signature was validated by Kaplan-Meier survival analysis. A signature-based risk score model divied patients into two risk group, and the recurrence-free survival rates of the groups were significantly different (log-rank p < 0.001). In addition, the ROC analysis showed that the lncRNA signature predictive ability was significantly better than that of age in the training/testing/entire group (AUC = 0.87/0.726/0.798 vs. AUC = 0.683/0.676/0.679). We constructed and verified a three-lncRNA signature predictive of recurrence, suggesting potential therapeutic targets for NFPA. |
format | Online Article Text |
id | pubmed-8564111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85641112021-11-04 A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas Cheng, Sen Guo, Jing Wang, Dawei Fang, Qiuyue Liu, Yulou Xie, Weiyan Zhang, Yazhuo Li, Chuzhong Front Genet Genetics The nonfunctioning pituitary adenoma (NFPA) recurrence rate is relatively high after surgical resection. Here, we constructed effective long noncoding RNA (lncRNA) signatures to predict NFPA prognosis. LncRNAs expression microarray sequencing profiles were obtained from 66 NFPAs. Sixty-six patients were randomly separated into a training (n = 33) and test group (n = 33). Univariable Cox regression and a machine learning algorithm was used to filter lncRNAs. Time-dependent receiver operating characteristic (ROC) analysis was performed to improve the prediction signature. Three lncRNAs (LOC101927765, RP11-23N2.4 and RP4-533D7.4) were included in a prognostic signature with high prediction accuracy for tumor recurrence, which had the largest area under ROC curve (AUC) value in the training/test group (AUC = 0.87/0.73). The predictive ability of the signature was validated by Kaplan-Meier survival analysis. A signature-based risk score model divied patients into two risk group, and the recurrence-free survival rates of the groups were significantly different (log-rank p < 0.001). In addition, the ROC analysis showed that the lncRNA signature predictive ability was significantly better than that of age in the training/testing/entire group (AUC = 0.87/0.726/0.798 vs. AUC = 0.683/0.676/0.679). We constructed and verified a three-lncRNA signature predictive of recurrence, suggesting potential therapeutic targets for NFPA. Frontiers Media S.A. 2021-10-20 /pmc/articles/PMC8564111/ /pubmed/34745223 http://dx.doi.org/10.3389/fgene.2021.754503 Text en Copyright © 2021 Cheng, Guo, Wang, Fang, Liu, Xie, Zhang and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Cheng, Sen Guo, Jing Wang, Dawei Fang, Qiuyue Liu, Yulou Xie, Weiyan Zhang, Yazhuo Li, Chuzhong A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas |
title | A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas |
title_full | A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas |
title_fullStr | A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas |
title_full_unstemmed | A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas |
title_short | A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas |
title_sort | novel three-lncrna signature predicting tumor recurrence in nonfunctioning pituitary adenomas |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564111/ https://www.ncbi.nlm.nih.gov/pubmed/34745223 http://dx.doi.org/10.3389/fgene.2021.754503 |
work_keys_str_mv | AT chengsen anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT guojing anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT wangdawei anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT fangqiuyue anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT liuyulou anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT xieweiyan anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT zhangyazhuo anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT lichuzhong anovelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT chengsen novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT guojing novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT wangdawei novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT fangqiuyue novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT liuyulou novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT xieweiyan novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT zhangyazhuo novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas AT lichuzhong novelthreelncrnasignaturepredictingtumorrecurrenceinnonfunctioningpituitaryadenomas |